However, Il17−/− mice had a lower liver-to-body weight ratio than Il17+/+ mice, suggesting that IL-17 deletion is a risk factor for NAFLD/NASH development (Fig. 2C). Here, IL17A is linked to metabolic dysfunction-associated steatohepatitis.